-+ 0.00%
-+ 0.00%
-+ 0.00%

TYRA BIOSCIENCES DOSES FIRST PATIENT IN PHASE 2 STUDY OF TYRA-300 IN LOW-GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (SURF302)

Reuters·06/30/2025 12:00:14

Please log in to view news